Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 2
2022 5
Text availability
Article attribute
Article type
Publication date

Search Results

7 results
Results by year
Filters applied: . Clear all
Page 1
Did you mean sutandi, s[au] (2 results)?
Cross-Neutralizing Activity Against SARS-CoV-2 Variants in COVID-19 Patients: Comparison of 4 Waves of the Pandemic in Japan.
Furukawa K, Tjan LH, Sutandhio S, Kurahashi Y, Iwata S, Tohma Y, Sano S, Nakamura S, Nishimura M, Arii J, Kiriu T, Yamamoto M, Nagano T, Nishimura Y, Mori Y. Furukawa K, et al. Among authors: sutandhio s. Open Forum Infect Dis. 2021 Aug 18;8(10):ofab430. doi: 10.1093/ofid/ofab430. eCollection 2021 Oct. Open Forum Infect Dis. 2021. PMID: 34631915 Free PMC article.
Seroepidemiological Survey of the Antibody for Severe Acute Respiratory Syndrome Coronavirus 2 with Neutralizing Activity at Hospitals: A Cross-sectional Study in Hyogo Prefecture, Japan.
Furukawa K, Arii J, Nishimura M, Tjan LH, Lystia Poetranto A, Ren Z, Aktar S, Huang JR, Sutandhio S, Kurahashi Y, Nishino A, Shigekuni S, Takeda Y, Uto K, Matsui K, Sato I, Inui Y, Endo K, Kosaka Y, Oota T, Saegusa J, Mori Y. Furukawa K, et al. Among authors: sutandhio s. JMA J. 2021 Jan 29;4(1):41-49. doi: 10.31662/jmaj.2020-0094. Epub 2021 Jan 14. JMA J. 2021. PMID: 33575502 Free PMC article.
Cross-Neutralizing Breadth and Longevity Against SARS-CoV-2 Variants After Infections.
Kurahashi Y, Sutandhio S, Furukawa K, Tjan LH, Iwata S, Sano S, Tohma Y, Ohkita H, Nakamura S, Nishimura M, Arii J, Kiriu T, Yamamoto M, Nagano T, Nishimura Y, Mori Y. Kurahashi Y, et al. Among authors: sutandhio s. Front Immunol. 2022 Feb 24;13:773652. doi: 10.3389/fimmu.2022.773652. eCollection 2022. Front Immunol. 2022. PMID: 35281007 Free PMC article.
Cross-neutralizing activity against Omicron could be obtained in SARS-CoV-2 convalescent patients who received two doses of mRNA vaccination.
Kurahashi Y, Furukawa K, Sutandhio S, Tjan LH, Iwata S, Sano S, Tohma Y, Ohkita H, Nakamura S, Nishimura M, Arii J, Kiriu T, Yamamoto M, Nagano T, Nishimura Y, Mori Y. Kurahashi Y, et al. Among authors: sutandhio s. J Infect Dis. 2022 May 5:jiac178. doi: 10.1093/infdis/jiac178. Online ahead of print. J Infect Dis. 2022. PMID: 35512332
Large-scale serosurveillance of COVID-19 in Japan: Acquisition of neutralizing antibodies for Delta but not for Omicron and requirement of booster vaccination to overcome the Omicron's outbreak.
Ren Z, Nishimura M, Tjan LH, Furukawa K, Kurahashi Y, Sutandhio S, Aoki K, Hasegawa N, Arii J, Uto K, Matsui K, Sato I, Saegusa J, Godai N, Takeshita K, Yamamoto M, Nagashima T, Mori Y. Ren Z, et al. Among authors: sutandhio s. PLoS One. 2022 Apr 5;17(4):e0266270. doi: 10.1371/journal.pone.0266270. eCollection 2022. PLoS One. 2022. PMID: 35381036 Free PMC article.